Testing a new antibody treatment for kidney protein disease

This is a Phase 2 trial testing budoprutug, a new antibody-based medication designed to treat primary membranous nephropathy, a kidney disease that causes too much protein to leak into the urine. The medication works by targeting and depleting specific immune cells (B cells) that are believed to cause kidney damage. About 45 patients with this condition will receive the treatment to see if it is safe and whether it can reduce protein in the urine.

Primary membranous nephropathy causes the kidneys to leak protein, which can damage kidney function over time. Many patients don't improve enough with currently available treatments, so researchers are testing whether this new medication can help people whose kidneys haven't responded to standard therapy.